Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $14.4 million.

  • Avalo Therapeutics' Cash from Financing Activities changed N/A to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.6 million, marking a year-over-year decrease of 2453.46%. This contributed to the annual value of $175.8 million for FY2024, which is 60221.63% up from last year.
  • According to the latest figures from Q3 2025, Avalo Therapeutics' Cash from Financing Activities is $14.4 million.
  • Avalo Therapeutics' Cash from Financing Activities' 5-year high stood at $108.6 million during Q1 2024, with a 5-year trough of -$14.8 million in Q2 2022.
  • Over the past 5 years, Avalo Therapeutics' median Cash from Financing Activities value was $10.7 million (recorded in 2023), while the average stood at $20.5 million.
  • Over the last 5 years, Avalo Therapeutics' Cash from Financing Activities had its largest YoY gain of 677080000.0% in 2024, and its largest YoY loss of 17892.98% in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Cash from Financing Activities stood at $76000.0 in 2021, then rose by 7.89% to $82000.0 in 2022, then plummeted by 98.78% to $1000.0 in 2023, then surged by 6770800.0% to $67.7 million in 2024, then tumbled by 78.78% to $14.4 million in 2025.
  • Its last three reported values are $14.4 million in Q3 2025, -$469000.0 for Q2 2025, and $67.7 million during Q4 2024.